On Aug. 4, 2020, Abiomed announced the FDA had issued an emergency use authorization (EUA) for its left-sided Impella heart pumps to provide left ventricular unloading and support to COVID-19 patients who are undergoing ECMO treatment and develop pulmonary edema or myocarditis.